MARA Holdings
MARA
MicroStrategy
MSTR
Coinbase
COIN
NVIDIA
NVDA
Tesla
TSLA
US Stock MarketDetailed Quotes
VERU Veru Inc
- 0.975
- +0.132+15.61%
Close Jan 17 16:00 ET
- 0.980
- +0.005+0.47%
Post 20:01 ET
142.78MMarket Cap-3.48P/E (TTM)
0.993High0.826Low4.91MVolume0.840Open0.844Pre Close4.57MTurnover4.17%Turnover RatioLossP/E (Static)146.38MShares1.92052wk High4.41P/B114.97MFloat Cap0.36052wk Low--Dividend TTM117.87MShs Float24.570Historical High--Div YieldTTM19.75%Amplitude0.271Historical Low0.929Avg Price1Lot Size
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Veru Inc Stock Forum
👀
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
Veru Inc. presented a meta-analysis of enobosarm's effects on body composition in older obese patients at ObesityWeek 2024. The analysis, based on four previous clinical trials, showed that enobosarm 3mg treatment led to better outcomes compared to placebo. By Day 147, enobosarm-treated subjects showed greater...
Veru Inc | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.6%)
Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress
Veru Inc. (NASDAQ: VERU) announced its participation in the World Obesity and Weight Management Congress, scheduled for October 24-26, 2024, in Baltimore, Maryland. The company will deliver a keynote presentation on October 25, 2024, f...
and 102 000 share to FISCH HARRY
Veru Reports Fiscal 2024 Second Quarter Financial Results and
Progress of its Enobosarm High Quality Weight Loss Clinical Program
—Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy®*) for highquality weight loss is actively enrolling—
—Company assembles esteemed high quality weight loss Scientific Advisory Board – five MDswith significant relevant medical, clinical and scientific expertise—
—Company to present this month at upcoming American Ass...
No comment yet